Indeed, in cancer cells treated with chemotherapeutic agents currently administered to CRC patients, accumulation of FOXO3a into the mitochondria has been found to promote chemoresistance and survival in a MEK/ERK-dependent manner (Figure 2). This evidence concerns the gene MAP2K7 and colorectal carcinoma.